Interesting BEAM Put And Call Options For January 2028

For Beam Therapeutics (BEAM), currently priced at $21.12, options analysis reveals two distinct strategies: selling the $20 strike put for a $5.00 premium offers an effective cost basis of $15.00, with a 77% chance of expiring worthless for a 25% return on cash commitment. Alternatively, a covered call strategy involving the $25 strike call, sold for $6.50, provides a potential 49.15% total return if shares are called away by January 2028, or a 30.78% premium yield if the call expires worthless. Notably, implied volatilities for these options (76-79%) are slightly above BEAM's 74% trailing twelve-month actual volatility.

Analysis

Analysis of options strategies for Beam Therapeutics (BEAM), trading at $21.12, reveals two distinct income-generating opportunities based on its January 2028 expiration contracts. For investors seeking to acquire the stock, selling the $20.00 strike put for a $5.00 premium establishes a potential cost basis of $15.00 per share, a significant discount to the current price. Analytical data indicates a 77% probability of this put expiring worthless, which would generate a 25.00% return on the cash commitment, equivalent to a 10.63% annualized yield. For current shareholders, a covered call strategy involving selling the $25.00 strike for a $6.50 premium offers a potential total return of 49.15% if the stock is called away. This strategy caps upside but provides a 30.78% yield boost (13.09% annualized) if the option expires worthless, an event with a 30% probability. Critically, the implied volatilities for the put (79%) and call (76%) are slightly elevated compared to BEAM's trailing twelve-month actual volatility of 74%, suggesting that option sellers are currently being well-compensated for taking on price risk.

Key Decisions for Investors

• Investors bullish on BEAM seeking to acquire shares should consider selling the $20 strike put to establish a potential cost basis of $15.00, which is significantly below the current market price, or to generate a 10.63% annualized yield.
• Current shareholders looking to generate income could evaluate selling the $25 covered call, which offers a 13.09% annualized yield enhancement but requires accepting a capped total return of 49.15% if the stock price appreciates beyond $25.
• Given that implied volatility of 76-79% is currently higher than the stock's 74% historical volatility, strategies focused on selling options premium, such as cash-secured puts and covered calls, are mathematically attractive at this time.
• Investors must recognize that these strategies are based on options pricing and technicals, and should conduct their own fundamental due diligence on Beam Therapeutics as a significant stock decline would lead to losses for the put seller.